TWIDH's Healthcare Pulse
This Week in Digital Health
Unlocking the future of healthcare. An insider's guide to game-changing digital innovations.
This past week's healthcare funding raised approximately $1.35 billion. Top Deals:
Funding
Marea Therapeutics , a San Francisco, California-based clinical-stage biotechnology company incubated by Third Rock Ventures, has raised a combined $190 million in Series A and Series B financing rounds. The Series A was led by Third Rock Ventures, while the Series B was led by Sofinnova Investments and co-led by Forbion, Perceptive Xontogeny Venture Fund, and venBio, with participation from Alpha Wave Global, Omega Funds, Surveyor Capital (a Citadel company), and founding investor Third Rock Ventures. Marea Therapeutics plans to use the funds to advance the Phase 2 development of its lead program MAR001 and support additional pipeline programs, leveraging its innovative approach to developing therapies for various diseases.
INSIGHTEC , a healthcare company with dual headquarters in Haifa, Israel, and Miami, Florida, has secured $150 million in equity funding. The company specializes in using focused ultrasound technology to enhance patient care. This funding round was led by Fidelity Management & Research Company and co-led by Nexus Neurotech Ventures and Ally Bridge Group. Other notable investors included Baillie Gifford, Catalio Capital Management, Fayez Sarofim & Co., Gilmartin Capital, York Global Finance / Community Fund, and Perceptive Advisors. Insightec plans to utilize this significant investment to expand its operations and further its development efforts in focused ultrasound technology for healthcare applications.
Talkiatry , a New York City-based provider of in-network psychiatric care, has raised $130 million in Series C funding. The round was led by Andreessen Horowitz (a16z), with participation from Perceptive Advisors and debt financing provided by Banc of California. Talkiatry plans to utilize the funds to enhance further and expand its value-based care model for behavioral health services. The investment will support the company's continued growth and development of its innovative approach to delivering accessible and effective mental health care.
BillionToOne , a precision diagnostics company headquartered in Menlo Park, California, has successfully raised $130 million in Series D funding, achieving a valuation of over $1 billion. The funding round was led by Premji Invest, with participation from new investor Neuberger Berman and existing investors, including Adam Street Partners, Baillie Gifford, Hummingbird Ventures, Civilization Ventures, Libertus Capital, and Fifty Years. As part of this investment, Akshay Rai, who led the Series D round, will join BillionToOne's Board of Directors. The company plans to utilize these funds to expand and scale its operations in prenatal and oncology diagnostics, furthering its mission in precision medicine.
Princeton Medspa Partners LLC (PMP), a Princeton, New Jersey-based national acquisition platform focused on the medical aesthetics market, has secured $120 million in growth financing. The investment was provided by BC Partners, an alternative assets firm managing approximately $40 billion in assets. PMP plans to utilize the capital for two key purposes: refinancing its existing credit facility and funding near-term acquisition opportunities to expand its network of medspas offering cosmetic treatments and aesthetic services across the United States. This major growth financing from BC Partners will enable PMP to accelerate its buy-and-build strategy within the rapidly growing medical aesthetics industry.
Elion Therapeutics , a New York City-based biotechnology company focused on developing treatments for life-threatening invasive fungal infections (IFIs), has secured $81 million through a Series B funding round. The investment was led by Deerfield Management and the AMR Action Fund, with additional participation from Illinois Ventures. Elion plans to deploy the newly raised capital to advance its lead candidate, SF001, a polyene antifungal therapeutic designed to have reduced toxicity compared to existing antifungal medications. The funds will support the progression of SF001 through clinical trials as the company works towards providing an improved treatment option for serious fungal infections.
iOnctura , a clinical-stage biopharmaceutical company based in Amsterdam, has secured €80 million in Series B funding. The round was led by Syncona, with additional participation from the European Innovation Council Fund and existing investors, including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund. The company plans to use this substantial funding to accelerate the development of its lead asset, roginolisib, primarily for treating uveal melanoma. Additionally, iOnctura will expand its clinical trials to other cancer indications, including non-small cell lung cancer and primary myelofibrosis, in 2024. This funding boost is expected to advance iOnctura's oncology research and development efforts significantly.
Enveda , a Boulder, Colorado-based biotechnology company leveraging AI to discover new medicines derived from natural sources, has raised an additional $55 million in a Series B2 funding round. Enveda's total funding is $230 million across its combined Series B rounds. The latest round was backed by new investors such as Premji Invest, Lingotto Investment Fund, Microsoft, The Nature Conservancy, and existing investors. Enveda will use the capital to develop its AI-powered drug discovery platform further, which has already yielded six new chemical entity development candidates. Funds will also support advancing Enveda's top three lead programs, including a novel oral treatment for atopic dermatitis, into Phase I clinical trials over the next year.
Iambic Therapeutics , a clinical-stage biotechnology company based in San Diego, California, has raised $50 million in a Series B extension funding round. The investment was led by Mubadala Capital and Exor Ventures, with participation from Qatar Investment Authority (QIA) and existing investors Abingworth, Illumina Ventures, Nexus Venture Partners, Coatue, and Tao Capital Partners. This extension adds to the $100 million Series B round closed in October 2023, co-led by Ascenta Capital and Abingworth, and joined by NVIDIA and others. Iambic Therapeutics plans to utilize the funds to advance further its pipeline of clinical and pre-clinical programs focused on developing innovative therapies.
Pomelo Care , a New York City-based virtual medical practice focused on improving maternal and newborn health outcomes, has raised $46 million in Series B funding. The round was co-led by First Round Capital and Andreessen Horowitz's Bio + Health fund, with additional participation from Stripes, SV Angel, Operator Partners, BoxGroup, and individual investors Adam Boehler and Puneet Singh. Pomelo Care plans to use this substantial investment to expand its partnerships with healthcare payors across the United States, aiming to broaden access to its virtual maternal and newborn care services.
瑞龙诺赋（上海）医疗科技有限公司 , a Shanghai-based medical technology company, has raised $44 million in Series B funding. The company specializes in developing innovative surgical robotics for soft tissue procedures. This funding round was co-led by Guolian Capital and INCE Capital, with additional participation from King Star Med LP and existing investor LongRiver Investments. Ronovo Surgical plans to use this substantial investment to accelerate the commercialization of its proprietary modular robotic system, the Carina? Platform, in the Chinese market. Additionally, the funding will support the company's plans for international expansion, potentially bringing its advanced surgical robotics technology to a global audience.
āshibio, Inc , a biotechnology company based in Brisbane, California, has secured $40 million in combined Seed and Series A funding. While the Seed round investors were not disclosed, the Series A round was led by MPM BioImpact, with participation from Agent Capital, YK Bioventures, and Mirae Asset Venture Investment. As part of the investment, Preston Noon, Partner and Co-Founder of Agent Capital, has joined āshibio's Board of Directors. The company plans to use this funding to advance the development of several investigative therapies, focusing on a potential treatment for fibrodysplasia ossificans progressiva (FOP). FOP is a rare genetic disorder characterized by abnormal bone formation in soft tissues, and āshibio's work aims to address this serious condition.
Rapafusyn Pharmaceuticals , a biotechnology company based in Baltimore, MD, has secured $28 million in Series A funding to advance its work on therapeutic drugs utilizing non-degrading molecular glues. The funding round was spearheaded by 3E Bioventures Capital and Proxima Ventures Ltd., with additional support from Lapam Capital. Specializing in discovering and developing macrocyclic peptide-based non-degrading molecular glues, Rapafusyn plans to use this capital infusion to accelerate its drug pipeline development and bolster its internal capabilities, potentially paving the way for innovative treatments in the pharmaceutical industry.
Humata Health , a Winter Park, Florida-based company, has raised $25 million in funding for its AI-driven prior authorization solutions for healthcare payers and providers. The funding round was led by Blue Venture Fund and LRVHealth, with participation from Optum Ventures, .406 Ventures, Highmark Ventures, and VentureforGood. Humata plans to use the capital to enhance its proprietary generative AI technologies, expand its customer base among healthcare providers, and initiate partnerships with payers and delegated entities. These efforts aim to streamline the prior authorization process through complementary solutions, ultimately improving efficiency in healthcare administration.
Nomad Health , a New York City-based digital marketplace for healthcare jobs, has raised $22 million in funding led by HealthQuest Capital. Other investors in the round included Adams Street, Icon Ventures, Polaris Partners, .406 Ventures, and RRE Ventures. The company has also appointed Justin Lambert as its new Chief Executive Officer. Nomad Health plans to use the funds to expand its product offerings and meet the growing demand for its staffing-enabling technology within the healthcare industry.
领英推荐
Ability Biologics , a Montreal, Canada-based cell targeting company, has raised $18 million in Seed funding. The round was led by Amplitude Ventures, with participation from FTQ, Investissement Québec, Charles River Laboratories, Theodorus, and Alexandria Venture Investments. Ability Biologics plans to use the funding to expand its operations and research and development efforts. The investment will support the company's development of innovative cell targeting technologies, likely aimed at advancing new therapeutics and diagnostics.
Vico Therapeutics , a clinical-stage genetic medicines company based in Leiden, The Netherlands, has secured an additional €11.5 million in the second closing of its Series B funding round. This investment, led by Seroba and Kurma Partners (via the Kurma Growth Opportunities Fund), brings the total Series B financing to €65.8 million ($70.7 million). They join existing investors, including Ackermans & van Haaren, Droia Ventures, EQT Life Sciences, Eurazeo, Kurma Biofund, Polaris Partners, and Pureos Bioventures. Vico Therapeutics plans to use these funds to advance its lead clinical program and further develop its portfolio of novel antisense oligonucleotides, potentially accelerating progress in genetic medicine development.
While nearly a quarter of the U.S. population struggles with mental illness or substance abuse disorders, only half receive needed mental health treatment, and a quarter get substance abuse care. Marigold Health aims to address this gap through an anonymous social network and AI-powered platform connecting people with certified peer recovery coaches 24/7. The company has raised $11 million in Series A funding co-led by Rock Health Capital and Innospark Ventures, with participation from Commonwealth Care Alliance, Wavemaker360, Stand Together Ventures Lab, Epsilon Health Investors, Koa Labs, VNS Health Plan, and KdT Ventures. Marigold partners with healthcare providers and payers like Medicaid plans to serve vulnerable populations needing mental health and addiction support.
Auxilius , a New York-based startup operating for four years, has raised a $10 million Series A1 funding round. The company offers software solutions for managing clinical trials' financial and accounting aspects. The investment round was led by SignalFire, with participation from XYZ, Renegade Partners, CP Overture, and previous investor Bain Capital Ventures. Auxilius will further utilize the funds to develop and enhance its software platform, which streamlines the financial management processes involved in clinical trials.
EpilepsyGTx , a London-based biotech company, has secured $10 million seed funding to advance its gene therapy research for focal refractory epilepsy. The funding round was led by UCL Technology Fund, with Health Technology Holding also participating. The company plans to use this capital to finalize preclinical studies for its lead gene therapy program, EPY201, and to prepare for a Phase 1/2a clinical trial in humans. This investment supports EpilepsyGTx's mission to develop innovative treatments for a challenging form of epilepsy, potentially offering new hope for patients with limited therapeutic options.
OCON Therapeutics, an Israeli health company based in Modiin, has raised $10 million to advance its drug delivery systems. The funding round was led by RH Capital, with additional support from Features Capital, Astia Angels, and Exerte Partners. Specializing in drug delivery systems, Ocon Therapeutics plans to use this capital to enhance its capabilities in developing solutions for treating common uterine pathologies. This investment could lead to improved treatments for various uterine conditions, furthering the company's mission in women's health.
Zing Coach?, a health tech startup based in Munich, Germany, has raised $10 million in Series A funding. Zubr Capital and Triple Point Capital led the round. The company, which develops an AI-powered fitness app, plans to use the new capital to enhance its product with new features, grow its team, and expand into new markets. This funding will support Zing Coach's efforts to innovate in the digital fitness space and broaden its user base internationally.
Tandem Health, a Swedish startup founded less than a year ago, has secured $9.5 million in seed funding. The company develops AI-powered software to streamline healthcare documentation by automatically generating medical notes from patient interactions. This innovative approach aims to reduce the administrative burden on healthcare providers, potentially improving efficiency and patient care. The funding round was led by Northzone, a prominent European venture capital firm, with participation from Amino Collective. This substantial seed investment in such a young company underscores the potential investors see in Tandem Health's AI-driven solution for the healthcare industry, particularly in addressing the growing challenge of documentation workload for medical professionals.
Sava, a London-based health monitoring company, has secured $8 million in Seed funding. The company specializes in providing a wearable biosensor platform for health monitoring. Balderton Capital and Exor Ventures led the funding round. Sava plans to use this capital to grow its team, design and manufacture its product line, and demonstrate the clinical performance of its biosensor platform. This funding will support Sava's efforts to advance its wearable health monitoring technology and establish its presence in the digital health market.
Alyve Health, a Mumbai, India-based health tech platform, has raised $5.5 million in funding led by Axilor Ventures, with participation from 1Crowd Fund, Inhealth Ventures, and venture debt funding from Trifecta Capital. The company plans to utilize the funds for strategic growth initiatives, including enhancing its platform, talent acquisition, expanding operations, amplifying services, and increasing member engagement. This investment round will support Alyve Health's efforts to scale its digital health offerings and establish its presence in India's rapidly growing health tech sector.
Jogo Health, a New York City-based medical technology company focused on treating chronic pain and neuromuscular disorders, has secured $5.5 million in funding. Hourglass Ventures led the investment round, and due to high demand, the company is opening the round to public retail investors through a Regulation CF community investment round on the Wefunder platform, allowing individual investors to join alongside firms like Mayo Clinic Ventures. Jogo Health plans to utilize the funds to expand its operations and further develop its products and services to address chronic pain and neuromuscular conditions.
Ethris, a Munich, Germany-based biotechnology company focused on developing next-generation RNA therapeutics and vaccines, has raised $5 million in funding from the Bill & Melinda Gates Foundation. The company plans to utilize the funds to accelerate its progress toward Phase 2 clinical readiness and establish the chemistry, manufacturing, and controls (CMC) processes required for the next stage of clinical trials. This funding from the Gates Foundation will support Ethris's efforts to advance its novel RNA-based therapeutic and vaccine candidates through further clinical development.
MEandMine, a Palo Alto-based startup focused on classroom well-being, has raised $4.5 million in funding. The company uses AI technology to identify psychological risks in young children within educational settings. K5 Global led the funding round. MEandMine plans to use the capital to expand its operations and further develop its AI-based risk identification platform for children's mental health in classrooms.
Coeptis Therapeutics, a biopharmaceutical company based in Wexford, PA, has secured $4.3 million in financing. The company, listed on Nasdaq under the ticker COEP, focuses on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. The funding round was spearheaded by CJC Investment Trust, an entity controlled by board member Christopher Calise. Coeptis plans to allocate the funds towards repaying outstanding debts, working capital, and general corporate purposes.
Primrose Bio, a San Diego-based company focused on developing and licensing its manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines, has received an undisclosed investment from 1315 Capital. The company plans to utilize the funds to enable the continued development and commercial expansion of its three offerings, which include manufacturing technologies for nucleic acids, proteins used in therapeutics, and vaccines. This investment will support Primrose Bio's efforts to further advance and commercialize its proprietary manufacturing platforms within the rapidly growing biotherapeutics and vaccine markets.
Aptatek Biosciences, a Princeton, New Jersey-based company developing in-home health monitoring solutions for patients with chronic diseases, has closed an undisclosed funding round. Canterbury Scientific, LDT, and the National PKU Alliance (NPKUA) led the investment after the successful initial clinical evaluation of Aptatek's first product. The company plans to use the funds to complete clinical studies of its groundbreaking in-home monitoring platform for the genetic disorder phenylketonuria (PKU), enabling patients to manage their condition from home better.
Promaxo, an Oakland, California-based company specializing in portable low-field MRI systems and minimally invasive robotics, has received an investment from Zynext Ventures, the venture capital arm of Zydus Lifesciences. While the exact amount of the investment was not disclosed, Promaxo plans to use the funds to expand its operations and further its development efforts in portable MRI technology and minimally invasive robotics. This investment could potentially accelerate Promaxo's growth and innovation in the medical imaging and robotics fields.
Funds
Nurse Capital, a Chicago-based venture capital firm focused on investing in nurse-led healthcare enterprises, has successfully closed its inaugural $1 million fund called the Nurse Founders Fund. This fund will provide late seed and Series A funding to startups founded and led by registered nurses developing innovative products, services, and solutions to enhance patient health and wellness, improve safety protocols, and pioneer advanced treatment approaches within the healthcare industry.